Skip to main content
. 2015 Jun;27(3):294–300. doi: 10.3978/j.issn.1000-9604.2015.05.03

Figure 1.

Figure 1

Progression-free survival (PFS) of patients carrying EGFR mutations treated with gefitinib in different mutation groups. S-A+, sequencing negative but ARMS positive; S+A+, sequencing positive and ARMS positive; log-rank, P=0.009; ARMS, Scorpion amplification refractory mutation system.